Molecular Evidence Reveals Thyrotropin Intervention Enhances the Risk of Developing Radioiodine-Refractory Differentiated Thyroid Carcinoma

Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share By

Molecular Evidence Reveals Thyrotropin Intervention Enhances the Risk of Developing Radioiodine-Refractory Differentiated Thyroid Carcinoma Publisher

Samimi H¹ ; Haghpanah V^{1, 2}

Source: Cancer Cell International Published:2022

Abstract

Radioiodine (RAI) is the mainstay of treatment for differentiated thyroid carcinoma (DTC) following total thyroidectomy. Nevertheless, about 5% of patients with DTC are RAI-refractory (RAI-R). Understanding the molecular mechanisms associated with DTC during progression towards RAI-R DTC, including thyroid-stimulating hormone levels, may help to explain the pathophysiology of challenging RAI-R DTC clinical cases. Graphical Abstract: [Figure not available: see fulltext.] © 2022, The Author(s).

Related Docs

View other Related Docs

1. Gut Microbiome and Radioiodine-Refractory Papillary Thyroid Carcinoma Pathophysiology, Trends in Endocrinology and Metabolism (2020)

2. Thyroid Cancer Research at Endocrinology and Metabolism Research Institute (Emri): A Report of Scientific Activities Between 2005 and 2020, Journal of Diabetes and Metabolic Disorders (2021)

3. Predictors of Success of the Ablative/Therapeutic Radioiodine (131I) in Differentiated Thyroid Cancer, Iranian Journal of Nuclear Medicine (2020)

Experts (# of related papers)

View all Related Experts

Alireza Emami Ardakani (4)

Babak Fallahi (4)

Other Related Docs

4. Application of Neck Technetium Uptake of the Neck in Post-Operation Ptc Patients for Detection of Forthcoming Iodine Ablation Response to Therapy, Indian Journal of Surgery (2022)

5. Predictors of Response to Radioactive Iodine Therapy in Intermediate and High Risk Patients With Papillary Thyroid Carcinoma, BMC Endocrine Disorders (2024)

6. Evaluation of Single Time Point Dosimetry Model for Personalized Radioiodine Therapy in Cancer Patients, Radiation Physics and Chemistry (2025)

7. The Role of External Beam Radiation Therapy in the Management of Thyroid Carcinomas: A Retrospective Study in Iran Cancer Institute, Cancer Reports (2023)

8. How to Manage Patients With Undetectable Thyroglobulin But Thyroid Residue After Radioiodine Ablative Therapy in Differentiated Thyroid Carcinoma, Retreatment or Observation?, Iranian Journal of Nuclear Medicine (2017)

9. Ultrasound-Guided Radiofrequency Ablation of Locally Recurrent Thyroid Carcinoma, CardioVascular and Interventional Radiology (2022)

10. Surgical Versus Non-Surgical Management of Hyperfunctional Thyroid Metastasis: A Case Report, Journal of Medical Case Reports (2024)

11. Changes in Salivary Gland Function Following Radioiodine Therapy of Thyroid Diseases: A Comparison of High-Dose Therapy for Thyroid Cancer and Low-Dose Therapy for Benign Thyroid Disease, Iranian Journal of Nuclear Medicine (2015)

12. Squamous Cell Carcinoma of the Lung and Pulmonary Metastasis of Papillary Thyroid Carcinoma: A Case Report, Journal of Medical Case Reports (2019)

13. A Practical Score Model for Detecting Malignant Thyroid Nodules by Using Ultrasonographic Findings, Acta Medica Iranica (2018)

14. Evaluation of Treatment Response and Survival Outcomes in Anaplastic Thyroid Cancer Patients Following Surgery With and Without Other Treatment Modalities: A Systematic Review, Health Science Reports (2025)

15. Papillary Thyroid Cancer With Metastases to Brain, Lung and Kidney: A Case of Dosimetry Proven Privilege of Surgical Resection of Organ Metastases, Iranian Journal of Nuclear Medicine (2018)

16. 3T Magnetic Resonance Spectroscopy As a Powerful Diagnostic Modality for Assessment of Thyroid Nodules, Archives of Endocrinology and Metabolism (2018)

17. Probiotic Bacteria Cannot Mitigate the Adverse Effects of Radioactive Iodine-131 Treatment, Cancers (2023)

18. The Evaluation of Locoregional Tumoral Involvement in the Cooccurrence of Hashimoto Thyroiditis With Papillary Thyroid Cancer: A Case Controlled Study, BMC Endocrine Disorders (2023)

19. Evaluation of Etiology, Clinical Manifestations, Diagnosis, Follow-Up, Histopathology and Prognosis Factors in Papillary Thyroid Microcarcinoma: A Systematic Review and Meta-Analysis, Iranian Journal of Pathology (2023)

20. What Features Predict Poorer Outcomes in Micropapillary Thyroid Carcinoma? a Retrospective Cohort Study, Endocrine Practice (2025)

Style	Citing Format
MLA	Samimi H, Haghpanah V. "Molecular Evidence Reveals Thyrotropin Intervention Enhances the Risk of Developing Radioiodine-Refractory Differentiated Thyroid Carcinoma." Cancer Cell International, vol. 22, no. 1, 2022, pp. -.
APA	Samimi H, Haghpanah V (2022). Molecular Evidence Reveals Thyrotropin Intervention Enhances the Risk of Developing Radioiodine-Refractory Differentiated Thyroid Carcinoma. Cancer Cell International, 22(1), -.
Chicago	Samimi H, Haghpanah V. "Molecular Evidence Reveals Thyrotropin Intervention Enhances the Risk of Developing Radioiodine-Refractory Differentiated Thyroid Carcinoma." Cancer Cell International 22, no. 1 (2022): -.
Harvard	Samimi H, Haghpanah V (2022) 'Molecular Evidence Reveals Thyrotropin Intervention Enhances the Risk of Developing Radioiodine-Refractory Differentiated Thyroid Carcinoma', Cancer Cell International, 22(1), pp. -.
Vancouver	Samimi H, Haghpanah V. Molecular Evidence Reveals Thyrotropin Intervention Enhances the Risk of Developing Radioiodine-Refractory Differentiated Thyroid Carcinoma. Cancer Cell International. 2022;22(1):-.
BibTex	@article{ author = {Samimi H and Haghpanah V}, title = {Molecular Evidence Reveals Thyrotropin Intervention Enhances the Risk of Developing Radioiodine-Refractory Differentiated Thyroid Carcinoma}, journal = {Cancer Cell International}, volume = {22}, number = {1}, pages = {-}, year = {2022} }
RIS	TY - JOUR AU - Samimi H AU - Haghpanah V TI - Molecular Evidence Reveals Thyrotropin Intervention Enhances the Risk of Developing Radioiodine-Refractory Differentiated Thyroid Carcinoma JO - Cancer Cell International VL - 22 IS - 1 SP - EP - PY - 2022 ER -